Teresa Montiel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Teresa Montiel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Lourdes Massieu
División de Neurociencias. Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México, CP, 04510, México.
3 shared publications - Berenice N. Bernal-Vicente
Departamento de Neuropatología Molecular División de Neurociencias Instituto de Fisiología Celular Universidad Nacional Autónoma de México Ciudad de México Mexico
1 shared publication - Cristian Gerónimo-Olvera
Center for Integrative Biology, Faculty of Sciences, Universidad Mayor, Santiago, Chile
1 shared publication - Juan Carlos Gómora-García
Departamento de Neuropatología Molecular División de Neurociencias Instituto de Fisiología Celular Universidad Nacional Autónoma de México Ciudad de México Mexico
1 shared publication - Lizbeth García-Velázquez
División de Neurociencias. Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México, CP, 04510, México
1 shared publication - Luis Angel Montes-Ortega
Departamento de Neuropatología Molecular, División de Neurociencias. Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, CP 04510, Ciudad de México. Mexico
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Autophagy-Lysosomal Axis Stimulation by Beta-Hydroxybutyrate in Astrocytes
The online version contains supplementary material available at 10.1007/s12035-026-05852-6.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Open AccessAutophagy-Lysosomal Axis Stimulation by Beta-Hydroxybutyrate in Astrocytes
The online version contains supplementary material available at 10.1007/s12035-026-05852-6.
- Open Access
- 16 June 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 166 (1) , 87-106
Modulation of the autophagy‐lysosomal pathway and endoplasmic reticulum stress by ketone bodies in experimental models of stroke
Ischemic stroke is a leading cause of disability worldwide. There is no simple treatment to alleviate ischemic brain injury, as thrombolytic therapy is applicable within a narrow time window. During the last years, the ketogenic diet (KD) and the exogenous administration of the ketone body β‐hydroxybutyrate (BHB) have been proposed as therapeutic tools for acute neurological disorders and both can reduce ischemic brain injury. However, the mechanisms involved are not completely clear. We have previously shown that the D enantiomer of BHB stimulates the autophagic flux in cultured neurons exposed to glucose deprivation (GD) and in the brain of hypoglycemic rats. Here, we have investigated the effect of the systemic administration of D‐BHB, followed by its continuous infusion after middle cerebral artery occlusion (MCAO), on the autophagy‐lysosomal pathway and the activation of the unfolded protein response (UPR). Results show for the first time that the protective effect of BHB against MCAO injury is enantiomer selective as only D‐BHB, the physiologic enantiomer of BHB, significantly reduced brain injury. D‐BHB treatment prevented the cleavage of the lysosomal membrane protein LAMP2 and stimulated the autophagic flux in the ischemic core and the penumbra. In addition, D‐BHB notably reduced the activation of the PERK/eIF2α/ATF4 pathway of the UPR and inhibited IRE1α phosphorylation. L‐BHB showed no significant effect relative to ischemic animals. In cortical cultures under GD, D‐BHB prevented LAMP2 cleavage and decreased lysosomal number. It also abated the activation of the PERK/eIF2α/ATF4 pathway, partially sustained protein synthesis, and reduced pIRE1α. In contrast, L‐BHB showed no significant effects. Results suggest that protection elicited by D‐BHB treatment post‐ischemia prevents lysosomal rupture allowing functional autophagy, preventing the loss of proteostasis and UPR activation. image
- 16 June 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 166 (1) , 87-106
Open AccessModulation of the autophagy‐lysosomal pathway and endoplasmic reticulum stress by ketone bodies in experimental models of stroke
Ischemic stroke is a leading cause of disability worldwide. There is no simple treatment to alleviate ischemic brain injury, as thrombolytic therapy is applicable within a narrow time window. During the last years, the ketogenic diet (KD) and the exogenous administration of the ketone body β‐hydroxybutyrate (BHB) have been proposed as therapeutic tools for acute neurological disorders and both can reduce ischemic brain injury. However, the mechanisms involved are not completely clear. We have previously shown that the D enantiomer of BHB stimulates the autophagic flux in cultured neurons exposed to glucose deprivation (GD) and in the brain of hypoglycemic rats. Here, we have investigated the effect of the systemic administration of D‐BHB, followed by its continuous infusion after middle cerebral artery occlusion (MCAO), on the autophagy‐lysosomal pathway and the activation of the unfolded protein response (UPR). Results show for the first time that the protective effect of BHB against MCAO injury is enantiomer selective as only D‐BHB, the physiologic enantiomer of BHB, significantly reduced brain injury. D‐BHB treatment prevented the cleavage of the lysosomal membrane protein LAMP2 and stimulated the autophagic flux in the ischemic core and the penumbra. In addition, D‐BHB notably reduced the activation of the PERK/eIF2α/ATF4 pathway of the UPR and inhibited IRE1α phosphorylation. L‐BHB showed no significant effect relative to ischemic animals. In cortical cultures under GD, D‐BHB prevented LAMP2 cleavage and decreased lysosomal number. It also abated the activation of the PERK/eIF2α/ATF4 pathway, partially sustained protein synthesis, and reduced pIRE1α. In contrast, L‐BHB showed no significant effects. Results suggest that protection elicited by D‐BHB treatment post‐ischemia prevents lysosomal rupture allowing functional autophagy, preventing the loss of proteostasis and UPR activation. image
- 6 May 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (12) , 1377-1387
Treatment with the Ketone Body D-β-hydroxybutyrate Attenuates Autophagy Activated by NMDA and Reduces Excitotoxic Neuronal Damage in the Rat Striatum In Vivo
Background: The ketone bodies (KB), β-hydroxybutyrate (BHB) and acetoacetate, have been proposed for the treatment of acute and chronic neurological disorders, however, the molecular mechanisms involved in KB protection are not well understood. KB can substitute for glucose and support mitochondrial metabolism increasing cell survival. We have reported that the D-isomer of BHB (D-BHB) stimulates autophagic degradation during glucose deprivation in cultured neurons increasing cell viability. Autophagy is a lysosomal degradation process of damaged proteins and organelles activated during nutrient deprivation to obtain building blocks and energy. However, impaired or excessive autophagy can contribute to neuronal death. Objective: The aim of the present study was to test whether D-BHB can preserve autophagic function in an in vivo model of excitotoxic damage induced by the administration of the glutamate receptor agonist, N-methyl-Daspartate (NMDA), in the rat striatum. Methods: D-BHB was administered through an intravenous injection followed by either an intraperitoneal injection (i.v+i.p) or a continuous epidural infusion (i.v+pump), or through a continuous infusion of D-BHB alone. Changes in the autophagy proteins ATG7, ATG5, BECLIN 1 (BECN1), LC3, Sequestrosome1/p62 (SQSTM1/ p62) and the lysosomal membrane protein LAMP2, were evaluated by immunoblot. The lesion volume was measured in cresyl violet-stained brain sections. Results: Autophagy is activated early after NMDA injection but autophagic degradation is impaired due to the cleavage of LAMP2. Twenty-four h after NMDA intrastriatal injection, the autophagic flux is re-established, but LAMP2 cleavage is still observed. The administration of D-BHB through the i.v+pump protocol reduced the content of autophagic proteins and the cleavage of LAMP2, suggesting decreased autophagosome formation and lysosomal membrane preservation, improving autophagic degradation. D-BHB also reduced brain injury. The i.v+i.p administration protocol and the infusion of D-BHB alone showed no effect on autophagy activation or degradation.
- 6 May 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (12) , 1377-1387
Treatment with the Ketone Body D-β-hydroxybutyrate Attenuates Autophagy Activated by NMDA and Reduces Excitotoxic Neuronal Damage in the Rat Striatum In Vivo
Background: The ketone bodies (KB), β-hydroxybutyrate (BHB) and acetoacetate, have been proposed for the treatment of acute and chronic neurological disorders, however, the molecular mechanisms involved in KB protection are not well understood. KB can substitute for glucose and support mitochondrial metabolism increasing cell survival. We have reported that the D-isomer of BHB (D-BHB) stimulates autophagic degradation during glucose deprivation in cultured neurons increasing cell viability. Autophagy is a lysosomal degradation process of damaged proteins and organelles activated during nutrient deprivation to obtain building blocks and energy. However, impaired or excessive autophagy can contribute to neuronal death. Objective: The aim of the present study was to test whether D-BHB can preserve autophagic function in an in vivo model of excitotoxic damage induced by the administration of the glutamate receptor agonist, N-methyl-Daspartate (NMDA), in the rat striatum. Methods: D-BHB was administered through an intravenous injection followed by either an intraperitoneal injection (i.v+i.p) or a continuous epidural infusion (i.v+pump), or through a continuous infusion of D-BHB alone. Changes in the autophagy proteins ATG7, ATG5, BECLIN 1 (BECN1), LC3, Sequestrosome1/p62 (SQSTM1/ p62) and the lysosomal membrane protein LAMP2, were evaluated by immunoblot. The lesion volume was measured in cresyl violet-stained brain sections. Results: Autophagy is activated early after NMDA injection but autophagic degradation is impaired due to the cleavage of LAMP2. Twenty-four h after NMDA intrastriatal injection, the autophagic flux is re-established, but LAMP2 cleavage is still observed. The administration of D-BHB through the i.v+pump protocol reduced the content of autophagic proteins and the cleavage of LAMP2, suggesting decreased autophagosome formation and lysosomal membrane preservation, improving autophagic degradation. D-BHB also reduced brain injury. The i.v+i.p administration protocol and the infusion of D-BHB alone showed no effect on autophagy activation or degradation.